Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older—A Population-Based Cohort Study

This population-based cohort study evaluates the risk of cardiac arrhythmia and other cardiovascular events in patients 66 years or older receiving the β3-adrenoceptor agonist mirabegron.

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Intern Med
Asıl Yazarlar: Tadrous, Mina, Matta, Rano, Greaves, Simon, Herschorn, Sender, Mamdani, Muhammad M., Juurlink, David N., Gomes, Tara
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2019
Konular:
Research Letter
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6632155/
https://ncbi.nlm.nih.gov/pubmed/31305875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2019.2011
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller